Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Index by author

April 01, 1995; Volume 47,Issue 4
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Abraham, P

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;
  2. Aduma, P

    1. You have access
      Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
      P Aduma, M C Connelly, R V Srinivas and A Fridland
      Molecular Pharmacology April 1995, 47 (4) 816-822;
  3. Allen, R A

    1. You have access
      Stimulation of type II adenylyl cyclase by chemoattractant formyl peptide and C5a receptors.
      R C Tsu, R A Allen and Y H Wong
      Molecular Pharmacology April 1995, 47 (4) 835-841;
  4. Andexinger, S

    1. You have access
      Sequestration and recycling of beta 2-adrenergic receptors permit receptor resensitization.
      S Pippig, S Andexinger and M J Lohse
      Molecular Pharmacology April 1995, 47 (4) 666-676;
  5. Asselin, J

    1. You have access
      Ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and the tyrphostin ST271 inhibit phospholipase C in human platelets by preventing Ca2+ entry.
      S P Watson, A Poole and J Asselin
      Molecular Pharmacology April 1995, 47 (4) 823-830;
  6. Aversa, C R

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

B

  1. Basha, F

    1. You have access
      Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;
  2. Becker, M A

    1. You have access
      Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine-5'- monophosphate: evidence for interaction at the ADP allosteric site.
      D W Fry, M A Becker and R L Switzer
      Molecular Pharmacology April 1995, 47 (4) 810-815;
  3. Ber, E

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  4. Berg, D K

    1. You have access
      Novel subpopulation of neuronal acetylcholine receptors among those binding alpha-bungarotoxin.
      P C Pugh, R A Corriveau, W G Conroy and D K Berg
      Molecular Pharmacology April 1995, 47 (4) 717-725;
  5. Billingsley, M L

    1. You have access
      Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;
  6. Boja, J W

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;
  7. Brady, C L

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;
  8. Brandt, T L

    1. You have access
      Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells.
      D J Fraser, T L Brandt and D J Kroll
      Molecular Pharmacology April 1995, 47 (4) 696-706;
  9. Bresnick, E

    1. You have access
      Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins.
      I Chung and E Bresnick
      Molecular Pharmacology April 1995, 47 (4) 677-685;
  10. Brittain, R J

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;
  11. Brüne, B

    1. You have access
      Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds.
      U K Messmer, E G Lapetina and B Brüne
      Molecular Pharmacology April 1995, 47 (4) 757-765;
  12. Budzik, G P

    1. You have access
      Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;
  13. Busconi, L

    1. You have access
      Recombinant endothelial nitric oxide synthase: post-translational modifications in a baculovirus expression system.
      L Busconi and T Michel
      Molecular Pharmacology April 1995, 47 (4) 655-659;

C

  1. Cadet, J L

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;
  2. Carroll, F I

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;
  3. Carter, G W

    1. You have access
      Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;
  4. Cascieri, M A

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  5. Castro, M A

    1. You have access
      Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain.
      J Garzon, J L Juarros, M A Castro and P Sanchez-Blazquez
      Molecular Pharmacology April 1995, 47 (4) 738-744;
  6. Chao, C C

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;
  7. Chung, I

    1. You have access
      Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins.
      I Chung and E Bresnick
      Molecular Pharmacology April 1995, 47 (4) 677-685;
  8. Connelly, M C

    1. You have access
      Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
      P Aduma, M C Connelly, R V Srinivas and A Fridland
      Molecular Pharmacology April 1995, 47 (4) 816-822;
  9. Conroy, W G

    1. You have access
      Novel subpopulation of neuronal acetylcholine receptors among those binding alpha-bungarotoxin.
      P C Pugh, R A Corriveau, W G Conroy and D K Berg
      Molecular Pharmacology April 1995, 47 (4) 717-725;
  10. Corriveau, R A

    1. You have access
      Novel subpopulation of neuronal acetylcholine receptors among those binding alpha-bungarotoxin.
      P C Pugh, R A Corriveau, W G Conroy and D K Berg
      Molecular Pharmacology April 1995, 47 (4) 717-725;

D

  1. Damuni, Z

    1. You have access
      Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;
  2. Díaz, R S

    1. You have access
      Protein-independent lead permeation through myelin lipid liposomes.
      R S Díaz and J Monreal
      Molecular Pharmacology April 1995, 47 (4) 766-771;
  3. Donnelly, J L

    1. You have access
      Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

E

  1. Eddlestone, G T

    1. You have access
      Mastoparan increases the intracellular free calcium concentration in two insulin-secreting cell lines by inhibition of ATP-sensitive potassium channels.
      G T Eddlestone, M Komatsu, L Shen and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 787-797;
  2. Epand, R M

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

F

  1. Feldman, R I

    1. You have access
      Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.
      J M Wu, D O Hoang and R I Feldman
      Molecular Pharmacology April 1995, 47 (4) 871-881;
  2. Findlay, D M

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;
  3. Fleming, W W

    1. You have access
      Adaptive supersensitivity and the Na+/K+ pump in the guinea pig vas deferens: time course of the decline in the alpha 2 subunit.
      K M Hershman, D A Taylor and W W Fleming
      Molecular Pharmacology April 1995, 47 (4) 726-729;
  4. Fraser, D J

    1. You have access
      Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells.
      D J Fraser, T L Brandt and D J Kroll
      Molecular Pharmacology April 1995, 47 (4) 696-706;
  5. Fridland, A

    1. You have access
      Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
      P Aduma, M C Connelly, R V Srinivas and A Fridland
      Molecular Pharmacology April 1995, 47 (4) 816-822;
  6. Friedman, E

    1. You have access
      Beta-adrenoceptor-G alpha S coupling decreases with age in rat aorta.
      H Gurdal, E Friedman and M D Johnson
      Molecular Pharmacology April 1995, 47 (4) 772-778;
  7. Fry, D W

    1. You have access
      Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine-5'- monophosphate: evidence for interaction at the ADP allosteric site.
      D W Fry, M A Becker and R L Switzer
      Molecular Pharmacology April 1995, 47 (4) 810-815;

G

  1. Garver, T D

    1. You have access
      Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;
  2. Garzon, J

    1. You have access
      Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain.
      J Garzon, J L Juarros, M A Castro and P Sanchez-Blazquez
      Molecular Pharmacology April 1995, 47 (4) 738-744;
  3. Gurdal, H

    1. You have access
      Beta-adrenoceptor-G alpha S coupling decreases with age in rat aorta.
      H Gurdal, E Friedman and M D Johnson
      Molecular Pharmacology April 1995, 47 (4) 772-778;

H

  1. Harris, K A

    1. You have access
      Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;
  2. Hershman, K M

    1. You have access
      Adaptive supersensitivity and the Na+/K+ pump in the guinea pig vas deferens: time course of the decline in the alpha 2 subunit.
      K M Hershman, D A Taylor and W W Fleming
      Molecular Pharmacology April 1995, 47 (4) 726-729;
  3. Hoang, D O

    1. You have access
      Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.
      J M Wu, D O Hoang and R I Feldman
      Molecular Pharmacology April 1995, 47 (4) 871-881;
  4. Houssami, S

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

I

  1. Ishimoto, H

    1. You have access
      Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells.
      I Matsuoka, Q Zhou, H Ishimoto and H Nakanishi
      Molecular Pharmacology April 1995, 47 (4) 855-862;

J

  1. Johnson, M D

    1. You have access
      Beta-adrenoceptor-G alpha S coupling decreases with age in rat aorta.
      H Gurdal, E Friedman and M D Johnson
      Molecular Pharmacology April 1995, 47 (4) 772-778;
  2. Juarros, J L

    1. You have access
      Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain.
      J Garzon, J L Juarros, M A Castro and P Sanchez-Blazquez
      Molecular Pharmacology April 1995, 47 (4) 738-744;

K

  1. Kelly, K M

    1. You have access
      Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;
  2. Kim, G

    1. You have access
      Effects of chromium on basal and insulin-induced tyrosine phosphorylation in H4 hepatoma cells: comparison with phorbol-12-myristate-13-acetate and sodium orthovanadate.
      E J Yurkow and G Kim
      Molecular Pharmacology April 1995, 47 (4) 686-695;
  3. Klinghofer, V

    1. You have access
      Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;
  4. Komatsu, M

    1. You have access
      Mastoparan increases the intracellular free calcium concentration in two insulin-secreting cell lines by inhibition of ATP-sensitive potassium channels.
      G T Eddlestone, M Komatsu, L Shen and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 787-797;
  5. Kopajtic, T A

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;
  6. Kroll, D J

    1. You have access
      Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells.
      D J Fraser, T L Brandt and D J Kroll
      Molecular Pharmacology April 1995, 47 (4) 696-706;
  7. Kuk, J E

    1. You have access
      Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;
  8. Kusaka, M

    1. You have access
      Direct block of calcium channels by dioctanoylglycerol in pregnant rat myometrial cells.
      M Kusaka and N Sperelakis
      Molecular Pharmacology April 1995, 47 (4) 842-847;

L

  1. Lapetina, E G

    1. You have access
      Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds.
      U K Messmer, E G Lapetina and B Brüne
      Molecular Pharmacology April 1995, 47 (4) 757-765;
  2. Lehman, R A

    1. You have access
      Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;
  3. Lever, J

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;
  4. Lewin, A H

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;
  5. Liu, E C

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;
  6. Lohse, M J

    1. You have access
      Sequestration and recycling of beta 2-adrenergic receptors permit receptor resensitization.
      S Pippig, S Andexinger and M J Lohse
      Molecular Pharmacology April 1995, 47 (4) 666-676;

M

  1. MacCoss, M

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  2. MacDonald, R L

    1. You have access
      Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;
  3. Martin, T J

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;
  4. Massa, E

    1. You have access
      Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;
  5. Matsuoka, I

    1. You have access
      Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells.
      I Matsuoka, Q Zhou, H Ishimoto and H Nakanishi
      Molecular Pharmacology April 1995, 47 (4) 855-862;
  6. Messmer, U K

    1. You have access
      Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds.
      U K Messmer, E G Lapetina and B Brüne
      Molecular Pharmacology April 1995, 47 (4) 757-765;
  7. Michel, T

    1. You have access
      Recombinant endothelial nitric oxide synthase: post-translational modifications in a baculovirus expression system.
      L Busconi and T Michel
      Molecular Pharmacology April 1995, 47 (4) 655-659;
  8. Mills, S G

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  9. Monreal, J

    1. You have access
      Protein-independent lead permeation through myelin lipid liposomes.
      R S Díaz and J Monreal
      Molecular Pharmacology April 1995, 47 (4) 766-771;
  10. Moore, E E

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;
  11. Murayama, E

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

N

  1. Nahorski, S R

    1. You have access
      Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
      J R Traynor and S R Nahorski
      Molecular Pharmacology April 1995, 47 (4) 848-854;
  2. Nakane, M

    1. You have access
      Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;
  3. Nakanishi, H

    1. You have access
      Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells.
      I Matsuoka, Q Zhou, H Ishimoto and H Nakanishi
      Molecular Pharmacology April 1995, 47 (4) 855-862;
  4. Neubauer, M

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

O

  1. Orlowski, R C

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;
  2. Oyler, G A

    1. You have access
      Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;

P

  1. Pippig, S

    1. You have access
      Sequestration and recycling of beta 2-adrenergic receptors permit receptor resensitization.
      S Pippig, S Andexinger and M J Lohse
      Molecular Pharmacology April 1995, 47 (4) 666-676;
  2. Polavarapu, R

    1. You have access
      Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;
  3. Pollock, J S

    1. You have access
      Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;
  4. Poole, A

    1. You have access
      Ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and the tyrphostin ST271 inhibit phospholipase C in human platelets by preventing Ca2+ entry.
      S P Watson, A Poole and J Asselin
      Molecular Pharmacology April 1995, 47 (4) 823-830;
  5. Pugh, P C

    1. You have access
      Novel subpopulation of neuronal acetylcholine receptors among those binding alpha-bungarotoxin.
      P C Pugh, R A Corriveau, W G Conroy and D K Berg
      Molecular Pharmacology April 1995, 47 (4) 717-725;

R

  1. Rizzo, M

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

S

  1. Sadowski, S

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  2. Sanchez-Blazquez, P

    1. You have access
      Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain.
      J Garzon, J L Juarros, M A Castro and P Sanchez-Blazquez
      Molecular Pharmacology April 1995, 47 (4) 738-744;
  3. Seltzman, H H

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;
  4. Sexton, P M

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;
  5. Shapiro, R A

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;
  6. Sharp, G W

    1. You have access
      Mastoparan increases the intracellular free calcium concentration in two insulin-secreting cell lines by inhibition of ATP-sensitive potassium channels.
      G T Eddlestone, M Komatsu, L Shen and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 787-797;
    2. You have access
      Unusual carbachol responses in RINm5F cells: evidence for a "distal" site of action in stimulus-secretion coupling.
      S H Tang, G C Yaney and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 863-870;
  7. Shen, L

    1. You have access
      Mastoparan increases the intracellular free calcium concentration in two insulin-secreting cell lines by inhibition of ATP-sensitive potassium channels.
      G T Eddlestone, M Komatsu, L Shen and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 787-797;
  8. Shiao, L L

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  9. Sperelakis, N

    1. You have access
      Direct block of calcium channels by dioctanoylglycerol in pregnant rat myometrial cells.
      M Kusaka and N Sperelakis
      Molecular Pharmacology April 1995, 47 (4) 842-847;
  10. Srinivas, R V

    1. You have access
      Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
      P Aduma, M C Connelly, R V Srinivas and A Fridland
      Molecular Pharmacology April 1995, 47 (4) 816-822;
  11. Strader, C D

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  12. Swain, C J

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  13. Switzer, R L

    1. You have access
      Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine-5'- monophosphate: evidence for interaction at the ADP allosteric site.
      D W Fry, M A Becker and R L Switzer
      Molecular Pharmacology April 1995, 47 (4) 810-815;

T

  1. Tamura, T

    1. You have access
      Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;
  2. Tang, S H

    1. You have access
      Unusual carbachol responses in RINm5F cells: evidence for a "distal" site of action in stimulus-secretion coupling.
      S H Tang, G C Yaney and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 863-870;
  3. Taylor, D A

    1. You have access
      Adaptive supersensitivity and the Na+/K+ pump in the guinea pig vas deferens: time course of the decline in the alpha 2 subunit.
      K M Hershman, D A Taylor and W W Fleming
      Molecular Pharmacology April 1995, 47 (4) 726-729;
  4. Traynor, J R

    1. You have access
      Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
      J R Traynor and S R Nahorski
      Molecular Pharmacology April 1995, 47 (4) 848-854;
  5. Treiger, B

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;
  6. Tsu, R C

    1. You have access
      Stimulation of type II adenylyl cyclase by chemoattractant formyl peptide and C5a receptors.
      R C Tsu, R A Allen and Y H Wong
      Molecular Pharmacology April 1995, 47 (4) 835-841;

U

  1. Uhler, M D

    1. You have access
      Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;

W

  1. Watson, S P

    1. You have access
      Ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and the tyrphostin ST271 inhibit phospholipase C in human platelets by preventing Ca2+ entry.
      S P Watson, A Poole and J Asselin
      Molecular Pharmacology April 1995, 47 (4) 823-830;
  2. Webb, M L

    1. You have access
      Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;
  3. Wong, Y H

    1. You have access
      Stimulation of type II adenylyl cyclase by chemoattractant formyl peptide and C5a receptors.
      R C Tsu, R A Allen and Y H Wong
      Molecular Pharmacology April 1995, 47 (4) 835-841;
  4. Wu, J M

    1. You have access
      Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.
      J M Wu, D O Hoang and R I Feldman
      Molecular Pharmacology April 1995, 47 (4) 871-881;
  5. Wu, M T

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  6. Wyrick, C D

    1. You have access
      Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

Y

  1. Yaney, G C

    1. You have access
      Unusual carbachol responses in RINm5F cells: evidence for a "distal" site of action in stimulus-secretion coupling.
      S H Tang, G C Yaney and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 863-870;
  2. Yu, H

    1. You have access
      Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;
  3. Yule, D I

    1. You have access
      Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;
  4. Yurkow, E J

    1. You have access
      Effects of chromium on basal and insulin-induced tyrosine phosphorylation in H4 hepatoma cells: comparison with phorbol-12-myristate-13-acetate and sodium orthovanadate.
      E J Yurkow and G Kim
      Molecular Pharmacology April 1995, 47 (4) 686-695;

Z

  1. Zhou, Q

    1. You have access
      Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells.
      I Matsuoka, Q Zhou, H Ishimoto and H Nakanishi
      Molecular Pharmacology April 1995, 47 (4) 855-862;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 47, Issue 4
1 Apr 1995
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics